Yasemin KARADENİZ BİLGİLİ, Figen COŞKUN, Sevilay VURAL, Nermin DİNDAR BADEM, Oğuz EROĞLU, Ertan COMERTPAY

The Diagnostic Value of sTWEAK in Acute Ischemic Stroke

Background: Considering the critical role of early diagnosis and management of acute ischemic stroke, biomarkers that can reliable assist in the diagnosis are still needed. These biomarkers should rapidly analyze, have high specificity for brain damage, and be available in the emergency settings for early diagnosis and exclusion of other conditions that mimic acute ischemic stroke. Soluble tumor necrosis factor-like weak inducer of apoptosis, a protein involved in the regulation of several biological functions, could be a potential acute ischemic stroke biomarker.Aims: To investigate the diagnostic value of soluble tumor necrosis factor-like weak inducer of apoptosis in patients with acute ischemic stroke and examine the relationship between ischemic area volume determined at diffusion-weighted magnetic resonance imaging and soluble tumor necrosis factor-like weak inducer of apoptosis.Study Design: A prospective, case-control study.Methods: This case-control prospective study included 36 patients with acute ischemic stroke and 36 healthy volunteers. Information on age, sex, presence of chronic disease, neurological examination findings, times of presentation to the emergency department after acuteischemicstroke,solubletumornecrosisfactor-likeweakinducer of apoptosis levels, ischemic area volumes at diffusion-weighted magnetic resonance imaging, and 6-month mortality rates after stroke were recorded. The results were analyzed on SPSS 22.0 software (SPSS Inc., Chicago, IL, USA), and p

PDF

___

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292.
2. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018;49:e46-99.
3. Musuka TD, Wilton SB, Traboulsi M, Hill MD. Diagnosis and management of acute ischemic stroke: speed is critical. CMAJ 2015;187:887-93.
4. Moseley ME, Kucharczyk J, Mintorovitch J, Cohen Y, Kurhanewicz J, Derugin N, et al. Diffusion-weighted MR imaging of acute stroke: correlation of T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR 1990;11:423-9.
5. Hjort N, Christensen S, Solling C, Ashkanian M, Wu O, Røhl L, et al. Ischemic injury detected by diffusion imaging 11 minutes after stroke. Ann Neurol 2005;58:462-5.
6. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40:1-16.
7. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241-9.
8. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003;162:1313-21.
9. Ortiz A, Sanchez-Nino M, Izquierdo M, Blanco-Colio LM, Selgas R, Ruiz-Ortega M, et al. TWEAK and the kidney: the dual role of a multifunctional cytokine. Adv Exp Med Biol 2011;691:323-35.
10. Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, Bellazzi R, et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 2010;85:681-90.
11. Inta I, Frauenknecht K, Dörr H, Kohlhof P, Rabsilber T, Auffarth GU, et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci 2008;275:117-20.
12. Yilmaz MS, Yilmaz M, Isik B, Yel C, Kavalci C, Demirci B, et al. The correlation of TWEAK level and with involved area on MRI in stroke. Biomed Res 2017;28:1110-4.
13. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenthal ES, Lev MH, et al. ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 2009;72:2104-10.
14. Vila N, Castillo J, Dávalos A, Chamorro Á. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000;31:2325-9.
15. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol 2012;74:230-40.
16. Schiff L, Hadker N, Weiser S, Rausch C. A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther 2012;16:79-92.
17. Lehmann MF, Kallaur AP, Oliveira SR, Alfieri DF, Delongui F, de Sousa Parreira J, et al. Inflammatory and metabolic markers and short-time outcome in patients with acute ischemic stroke in relation to TOAST subtypes. Metab Brain Dis 2015;30:1417- 28.
18. Doehner W, von Haehling S, Suhr J, Ebner N, Schuster A, Nagel E, et al. Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J Am Coll Cardiol 2012;60:346-54.
19. Kes VB, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008;41:1330-4.
20. Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, Saglam M, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1716-23.
21. Richter B, Rychli K, Hohensinner PJ, Berger R, Mörtl D, Neuhold S, et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 2010;213:545-8.
22. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009;11:1050-6.
23. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010;211:322-6.
24. Martín-Ventura J, Lindholt JS, Moreno J, Vega de Céniga M, Meilhac O, Michel JB, et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011;214:486-9.
25. Filusch A, Zelniker T, Baumgärtner C, Eschricht S, Frey N, Katus HA, et al. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. Clin Res Cardiol 2011;100:879-85.
26. Tong D, Yenari M, Albers G, O'brien M, Marks M, Moseley M. Correlation of perfusion-and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke. Neurology 1998;50:864-9.
27. Morita N, Harada M, Uno M, Matsubara S, Nagahiro S, Nishitani H. Evaluation of initial diffusion-weighted image findings in acute stroke patients using a semiquantitative score. Magn Reson Med Sci 2009;8:47-53.
28. Thijs VN, Lansberg MG, Beaulieu C, Marks MP, Moseley ME, Albers GW. Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? a multivariable analysis. Stroke 2000;31:2597-602.
29. Lin LC, Yang J, Weng H, Hsiao C, Lai SL, Fann W. Predictors of early clinical deterioration after acute ischemic stroke. Am J Emerg Med 2011;29:577-81.